UC BRAID Center for Accelerated Innovation

描述（由申请人提供）： 加州大学加速创新中心建议创建新的机制，并利用其在诊断、治疗和设备方面的不同优势，支持将有前途的早期发明转化为造福患者的成果。该中心是五个加州大学医学院的联盟：加州大学戴维斯分校，加州大学欧文分校，加州大学洛杉矶分校，加州大学圣地亚哥分校和加州大学旧金山弗朗西斯科分校。每个校区都有一个蓬勃发展的研究企业，全国排名的医学院，以及由临床和转化科学奖（CTSA）资助的转化研究所。加在一起，我们的五个校区占近7%的NHLBI的赠款资金。该中心利用加州传奇生物医学和工程生态系统的活力和创造力，并整合了我们校园内许多成功的商业，工程和健康科学课程。我们的计划将与成熟的生物医学公司，风险投资公司，行业组织和专注于医疗创新的非营利组织合作。该中心由UC生物医学研究加速，集成和开发（UC BRAID）支持，这是五个UC生物医学校区的共同努力，旨在促进和加速整个UC系统的生物医学，临床和转化研究。我们将共同：1）通过全面的教育，培训和导师计划，让加州心脏，肺和血液疾病创新者参与到医学中来。2)征集和选择具有高商业潜力的技术，这些技术符合NHLBI的使命，并解决未满足的医疗需求或重大科学机会。3)根据行业要求孵化我们最有前途的技术，以促进其转化为商业产品，改善患者护理和增强健康。4)创建高性能、可持续的基础设施，作为学术研究中心的典范。这些计划将创建一个综合的，可持续的基础设施，以加快我们的NHLBI资助的发现转化为市场，以促进健康和改善病人护理。 (End摘要）

DESCRIPTION (provided by applicant): The University of California Center for Accelerated Innovation proposes to create new mechanisms and to leverage its diverse strengths in diagnostics, therapeutics, and devices to support translation of promising early-stage inventions for patient benefit. The Center is a consortium of the five UC medical campuses: UC Davis, UC Irvine, UC Los Angeles, UC San Diego, and UC San Francisco. Each campus has a thriving research enterprise, nationally ranked medical school, and translational research institute funded by Clinical and Translational Science Awards (CTSA). Together, our five campuses account for nearly 7% of NHLBI's grant funding. The Center taps into the vigor and creativity of California's legendary biomedical and engineering ecosystem and integrates the many successful business, engineering and health sciences programs at our campuses. Our program will partner with well-established biomedical companies, venture capital firms, industry organizations and nonprofits focused on medical innovation. The Center is supported by UC Biomedical Research Acceleration, Integration, and Development (UC BRAID), a joint effort of the five UC biomedical campuses designed to catalyze and accelerate biomedical, clinical, and translational research across the UC system. Together we will: 1) Engage University of California heart, lung and blood disease innovators in entrepreneurism through a comprehensive education, training and mentorship program. 2) Solicit and select technologies with high commercial potential that align with NHLBI's mission and address unmet medical needs or significant scientific opportunity. 3) Incubate our most promising technologies in accordance with industry requirements to facilitate their translation to commercial products that improve patient care and enhance health. 4) Create a high-performing, sustainable infrastructure that will serve as a model to academic research centers. These programs will create an integrated, sustainable infrastructure to accelerate the translation of our NHLBI-funded discoveries to the marketplace in order to promote health and improve patient care. (End of Abstract)